Dehydration News and Research RSS Feed - Dehydration News and Research

Dehydration is a condition caused by the loss of too much water from the body. Severe diarrhea or vomiting can cause dehydration.
Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan plc today announced that SAPHRIS (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17). [More]
Vanderbilt doctors urge Middle Tennesseans to take extra care to avoid heat-related illnesses

Vanderbilt doctors urge Middle Tennesseans to take extra care to avoid heat-related illnesses

With temperatures holding steady in the upper 90s and even reaching 100 degrees this week, doctors at Vanderbilt University Medical Center are urging Middle Tennesseans to take extra precautions to avoid heat-related illnesses. [More]
UB researchers to study dangers that dehydration poses for U.S. Navy divers

UB researchers to study dangers that dehydration poses for U.S. Navy divers

Researchers at the University at Buffalo School of Public Health and Health Professions will study the dangers that dehydration presents for U.S. Navy divers, examining diver physiology both during and after underwater activities. [More]
Trial results show routine oral cholera vaccination programme protects people living in endemic regions

Trial results show routine oral cholera vaccination programme protects people living in endemic regions

An oral cholera vaccine given as part of routine health services is safe and protects against severe cholera in children and adults in urban Bangladesh where the disease is endemic, according to the first real-life trial of this vaccine published in The Lancet. [More]
New guidelines seek to protect athletes from exercise-associated hyponatremia

New guidelines seek to protect athletes from exercise-associated hyponatremia

While the risks of dehydration are well known, new international guidelines seek to protect athletes from the serious health risks associated with drinking too many fluids while exercising. [More]
UF researchers develop smart mouth guard to detect teeth grinding

UF researchers develop smart mouth guard to detect teeth grinding

Researchers at the University of Florida have developed a smart mouth guard equipped with sensors that allow it to detect if you're grinding your teeth, tell your dentist and even help you stop doing it. [More]

Improved medicine packaging designs increase caregivers' willingness to provide ORS to children

The usage of key medicines in developing countries could be significantly increased through improved packaging appearance, a new study by the Clinton Health Access Initiative, Inc. (CHAI) and the University of Warwick finds. [More]
Athletes need to drink when thirsty to avoid exercise-associated hyponatremia

Athletes need to drink when thirsty to avoid exercise-associated hyponatremia

For hikers, football players, endurance athletes, and a growing range of elite and recreational exercisers, the best approach to preventing potentially serious reductions in blood sodium level is to drink when thirsty, according to an updated consensus statement on exercise-associated hyponatremia (EAH). [More]
Spyryx receives award from Cystic Fibrosis Foundation to development therapeutic peptides for CF

Spyryx receives award from Cystic Fibrosis Foundation to development therapeutic peptides for CF

Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for obstructive lung diseases, announced today it has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of Spyryx' therapeutic peptides for cystic fibrosis (CF). [More]
CHLA researchers provide new hope for infants with short bowel syndrome

CHLA researchers provide new hope for infants with short bowel syndrome

Investigators at Children's Hospital Los Angeles are providing new hope for babies with short bowel syndrome (SBS) by developing a novel model of SBS in zebrafish, described in a paper published online on June 18 by the American Journal of Physiology-Gastrointestinal and Liver Physiology. [More]
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. [More]
Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Innovative QI program speeds recovery in patients undergoing colon and rectal operations

Patients undergoing colon and rectal operations who participated in an innovative quality improvement (QI) program to speed their recovery and enhance results experienced shorter hospitalizations, reduced infection rates, and lower hospital costs, according to new study results. [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone. [More]
New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. [More]
Mucus dehydration may contribute to chronic bronchitis

Mucus dehydration may contribute to chronic bronchitis

Mucus dehydration may lead to reduced mucociliary clearance and symptoms of chronic bronchitis, research suggests. [More]
New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

Physicians treating hospitalized patients for conditions unrelated to the kidneys should pay close attention to common blood and urine tests for kidney function in order to prevent incidental injury to the organs that help cleanse the body of toxins, new Johns Hopkins Bloomberg School of Public Health-led research suggests. [More]
Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). [More]
Advertisement
Advertisement